This is a Phase I/IIa, open-label, multicenter study to characterize safety and tolerability,
evaluate biodistribution, biological effects and immunogenicity, and evaluate the preliminary
clinical efficacy of SynOV1.1, when administered as monotherapy and in combination with
atezolizumab to participants with AFP positive HCC.
Part 1 (dose escalation) is designed to determine the pharmacodynamics of SynOV1.1 as well as
type and severity of toxicity based on safety and tolerability assessments. 3 dose level (3 ×
10^11, 1 × 10^12, 3 × 10^12) will be evaluated. Part 2 (combination therapy) is designed to
gather safety, tolerability, biodistribution data, and to evaluate the preliminary efficacy
of SynOV1.1 in combination with atezolizumab. Part 3 (expansion study) is designed to further
evaluate the efficacy SynOV1.1 in combination with atezolizumab in participants with HCC.
1. Voluntarily participates in the clinical trial study; fully understands the study and
signs the ICF; and is willing to follow and will be able to complete all trial
2. Is ≥18 years old when signing ICF; male or female.
3. Has locally advanced or metastatic AFP-positive primary hepatocellular carcinoma that
has relapsed or is refractory to standard cancer therapies (including sorafenib,
lenvatinib and atezolizumab plus bevacizumab combination), or where no standard
therapies are available. AFP positive means that serum samples have levels of AFP> 20
ng/ml during screening or an AFP immunohistochemistry [IHC] test of previous tumor
tissue samples was positive.
4. Has at least one lesion that cannot be surgically removed which can be injected
directly or through ultrasound (US) and/or computer tomography (CT) guidance.
5. Has at least one measurable tumor lesion.
6. Has a Child-Pugh score of Class A.
7. Has an ECOG performance status is 0 to 1 one week prior to the treatment.
8. Has an expected survival time of ≥ 12 weeks.
9. Has limited alterations in hematology or clinical chemistry: ANC≥ 1.5 × 10^9/L, PLT≥
75 × 109/L, TBIL≤ 1.5 ×ULN, AST and ALT≤5 × ULN, Alb≥ 2.8 g/dL, Crea≤ 1.5 × ULN, INR≤
1.5 × ULN.
10. Agrees to provide archived or fresh tumor tissue specimens according to the
individual's situation and blood samples.
11. A female participant who is postmenopausal, or whose serum pregnancy test result is
negative. A woman who has not experienced a menstrual period for 12 months due to
non-medical reasons is considered postmenopausal.
12. Female participants of child-bearing potential and male participants shall agree to
take medically acceptable contraception measures (hormones, barrier, or abstinence)
while on treatment and for 90 days following completion of treatment.
1. Received any anti-tumor treatment within the 4 weeks prior to study drug
administration. The anti-tumor treatment includes surgery, ethanol injection,
radiofrequency ablation, trans-arterial chemoembolization, intrahepatic chemotherapy,
chemotherapy, biotherapy, immunotherapy, hormone, or radiotherapy.
2. Received a systemic treatment of glucocorticoid (Prednisone > 10 mg/day or equivalent
dose of a similar medicine) or other immunosuppressant treatment 14 days prior to
study drug administration。
3. Administration of immune-regulating medicines within 14 days prior to study drug
administration of the investigational drug。
4. Administration of live-attenuated vaccines within 4 weeks prior to study drug
administration。 5.5.Previously treated with oncolytic viruses or other gene therapies.
6.Received treatment of unapproved investigational drugs within 4 weeks prior to study drug
7.Currently participating in another clinical study, except for an observational or genetic
(non-interventional) clinical study or a follow-up period.
8.Had major organ surgery (excluding biopsy) or had significant trauma within 4 weeks prior
to study drug administration.
9.An adverse event from the previous anti-tumor therapy that has not resolved to ≤ Grade 1
or stabilized according to NCI-CTCAE v5.0, except for the adverse event of non-risk
toxicity as judged by the investigator and sponsor.
10.Participants with clinical symptoms of central nervous system metastasis or meningeal
metastasis, or other evidence demonstrating the central nervous system metastasis or
meningeal metastasis has not been controlled.
11.History of meningococcal disease. 12.Evidence of uncontrolled severe comorbidity that
may affect the participant's compliance with the study protocol, including severe liver
disease (e.g. severe esophageal and gastric varices that require interventional treatment,
cirrhosis, hepatic encephalopathy, or venous syndrome).
13.History of serious cardiovascular disease。 14.Participants who have third interstitial
fluid beyond clinical control judged by the investigator.
15.History of tuberculosis infection or immunodeficiency, including participants who have
tested positive for the human immunodeficiency virus (HIV) antibody.
16.Participants who are allergic to any component of the SynOV1.1 drug product.
17.Participants who are intolerant or allergic to atezolizumab (only for Part II and Part
18.Participants who are suffering from a known mental illness or substance abuse that may
affect the objectivity of the trial.
19.Female participants who are pregnant, lactating, or who plan to get pregnant or to
breastfeed during the trial.
20.Other reasons as judged by the investigator, including but not limited to highly
vascularized tumors, exogenous, adjacent to necrotic areas, liver cysts, tumor site at the
location with high risk of adverse events or not suitable for intratumoral injection, or
tumor that will enhance the contraindications of CT/ MRI examination.
21.A significant bleeding event, as assessed by the investigator, that occurring within 12
months prior to study drug administration may increase the risk of intratumoral injection
22.Participants who cannot discontinue anticoagulant or antiplatelet medications prior to
the intratumoral injection of SynOV1.1.
23.Participants who require treatment for active systemic infection. 24.Participants who
have been diagnosed with bile duct cancer, bile duct liver cancer, fibrolamellar carcinoma,
or hepatoblastoma based on histological finding.
25.Participants who have a severe inflammatory skin disease that currently requires
medication or who have a history of severe eczema that requires medication.
26.Participants who received or plan to receive an organ transplant, such as a liver
27.Participants who carry another type of tumor that has required active treatment in the
past 5 years.